Multiple Myeloma Resources
Chosen by Advanced
Practice Providers
  • Clinical guidelines
  • Patient support and education resources
  • Research updates

Global Experts Tackle Infection Risks in Multiple Myeloma, Call for Unified Prevention Guidelines

In patients with multiple myeloma, infection is the primary cause of morbidity and mortality, influenced by a combination of the disease itself, treatments, and individual patient factors. The...
CURATED BY: Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

DREAMM-8 Trial: Belantamab Mafodotin Shows Promise in Treating Multiple Myeloma

GSK, the manufacturer of the antibody-drug conjugate belantamab mafodotin-blmf (Blenrep), has announced positive top-line findings from the phase 3 DREAMM-8 trial for belantamab mafodotin combined with pomalidomide and dexamethasone in...
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

FDA Panel Backs Cilta-cel for Relapsed/Refractory Multiple Myeloma Post-CARTITUDE-4 Success

The FDA’s Oncologic Drugs Advisory Committee unanimously voted that ciltacabtagene autoleucel (cilta-cel; Carvykti) offers more benefits than risks for treating adult patients with relapsed/refractory multiple myeloma who have had at...
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Study Reveals Poor Outcomes for Post-Anti-CD38 Therapy

A retrospective cohort study analyzed patients with multiple myeloma (MM) refractory to anti-CD38 monoclonal antibody therapy, involving 663 patients, with a focus on those with triple class refractory (TCR) disease....
CURATED BY:
Laura J. Zitella,
MS, RN, ACNP-BC, AOCN

Physician Associate and Nurse Practitioner Contributors to the Multiple Myeloma Center of Excellence

POCN’s Multiple Myeloma Center of Excellence is curated by nurse practitioners and practicing clinical physician associates who review and select resources that are the most useful to their peers. They provide their expertise by hand-picking the latest content for advanced practice providers.

Provided by an unrestricted grant from

Share